Výsledky vyhledávání - "Stephanie G. Willis"

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Autor: Oliver Hantschel, Richard D. Press, Michael W. Deininger, Ines Kaupe, Kim Hien T. Dao, Thoralf Lange, Lalita Prabha Turaga, Brian J. Druker, Stephanie G. Willis, Thomas Bumm, Daniel W. Sherbenou, Giulio Superti-Furga

Publikováno v: Blood. 116:3278-3285

Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL kinase inhibitors, including imatinib. It has also been shown in vitro that mutations outside

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa8ef2b1b85f4e59610b62313f346b1
https://doi.org/10.1182/blood-2008-10-183665

Zobrazit plný text záznamu

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib

Autor: Richard D. Press, Stephanie G. Willis, Michael W. Deininger, Michael J. Mauro, Jennifer Laudadio

Publikováno v: Blood. 114:2598-2605

In imatinib-treated chronic myeloid leukemia (CML), secondary drug resistance is often caused by mutations in the BCR-ABL kinase domain (KD). As alternative therapies are available for imatinib resistance, early identification of mutations may preven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49baa91c976da6020ca5f8499931dcdc
https://doi.org/10.1182/blood-2008-08-173674

Zobrazit plný text záznamu

Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation

Autor: Marc M. Loriaux, Michael W. Deininger, Stephanie G. Willis, Michael Rutenberg-Schoenberg, Thomas O'Hare, Heidi Erickson, B. J. Druker, Jeffrey W. Tyner

Publikováno v: Leukemia. 23:1345-1348

Therapies that are targeted to the molecular genetic defect of malignancies have proven more successful than conventional chemotherapeutic approaches.1, 2, 3, 4 A broad application of this strategy will require a detailed understanding of the genetic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a35cf2d61fff8af56e53e4a55f949cc1
https://doi.org/10.1038/leu.2009.66

Zobrazit plný text záznamu

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

Autor: Michael W. Deininger, Amie S. Corbin, Jutta Deininger, Stephanie G. Willis, Marc M. Loriaux, Thomas O'Hare, Keiichi I. Nakayama, Brian J. Druker, Jonathan VanDyke, Anupriya Agarwal, Thomas Bumm

Publikováno v: Blood. 112:1960-1970

BCR-ABL is proposed to impair cell-cycle control by disabling p27, a tumor suppressor that inhibits cyclin-dependent kinases. We show that in cell lines p27 expression is inversely correlated with expression of SKP2, the F-box protein of SCFSKP2 (SKP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::501d9f85095f85f066b17a70ab1bb9e1
https://doi.org/10.1182/blood-2007-09-113860

Zobrazit plný text záznamu

A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response

Autor: Stephanie G. Willis, Chad D. Galderisi, Carole Rempfer, Brian J. Druker, Rui Yang, Richard D. Press, Michael W. Deininger, Michael J. Mauro

Publikováno v: Clinical Cancer Research. 13:6136-6143

Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients relapse. Biomarkers capable of predicting those CCR patients with a hi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c9125d433d3eb330e33232c1e97050
https://doi.org/10.1158/1078-0432.ccr-07-1112

Zobrazit plný text záznamu

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Autor: Brian J. Druker, Lucy C. Crossman, Eric P. Stoffregen, Sandra Otto, Michael W. Deininger, Shannon K. McWeeney, Stephanie G. Willis, Byung Park, Dietger Niederwieser, Shadmehr Demehri, Thoralf Lange, Ines Kovacs

Publikováno v: Blood. 106:2128-2137

Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib resistance. In some cases, identical mutations were detected at relapse and in pretherapeutic specimens, consistent with selection of resistant clones in the pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f690705f56a1198b83df3b783d61a9
https://doi.org/10.1182/blood-2005-03-1036

Zobrazit plný text záznamu

Molecular Phylogenetic and Biogeochemical Studies of Sulfate-Reducing Bacteria in the Rhizosphere of Spartina alterniflora

Autor: Juliette N. Rooney-Varga, Stephanie G. Willis, Richard Devereux, Mark E. Hines, Robert S. Evans, Stephanie D. Friedman, Barbara R. Sharak Genthner

Publikováno v: Applied and Environmental Microbiology. 65:2209-2216

The population composition and biogeochemistry of sulfate-reducing bacteria (SRB) in the rhizosphere of the marsh grass Spartina alterniflora was investigated over two growing seasons by molecular probing, enumerations of culturable SRB, and measurem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4de7139fa862c5b4f910d0215c8814fd
https://doi.org/10.1128/aem.65.5.2209-2216.1999

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání